摘要
近年来,随着肝细胞癌基础研究不断深入,分子靶向药物及免疫治疗药物的临床开发及应用为肝细胞癌的治疗带来了新的突破。肝细胞癌的靶向治疗药物具有较高的特异性,能够选择性地杀伤肿瘤细胞,尽可能减少对正常组织的损伤。目前,这些靶向治疗药物主要分为小分子靶向药物、肝细胞癌抗原特异性靶向药物和免疫检验点靶向药物3类。现就肝细胞癌靶向治疗药物的最新研究进展作简要综述。
In recent years, with the deepening of basic research of hepatocellular carcinoma（HCC）, the clinical development and application of molecular targeted drugs and immunotherapeutic drugs have brought new breakthroughs in the treatment of hepatocellular carcinoma. Because of high specificity, targeted drugs can selectively kill tumor cells and as far as possibly reduce the damage to normal tissues. At present, targeted therapy drugs for HCC can be divided into three categories： small molecule targeted drugs, hepatocellular carcinoma antigen specific targeted drugs, and immune checkpoint targeted drugs. In this article, the latest progress of HCC targeted therapy was discussed.
作者
邱盛萍
黄承浩
QIU Sheng-Ping;HUANG Cheng-Hao(State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen 361102, China)
出处
《生命科学》
CSCD
北大核心
2018年第5期575-579,共5页
Chinese Bulletin of Life Sciences
关键词
肝细胞癌
靶向治疗
免疫检验点
hepatocellular carcinoma （HCC）
targeted therapy
immune checkpoint
